Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor Corporation (NYSE: DXR) announced an expert analysis titled, "Anemia and Heart Failure: Guidance for Clinicians and Trialists," published in the American College of Cardiology. This analysis highlights the significance of measuring total blood volume in managing anemia among heart failure patients, a condition affecting over 6 million Americans. Daxor's BVA-100 Blood Volume Analyzer is emphasized as a critical tool for accurate blood volume assessment, informing treatment strategies. The company is also developing new testing platforms supported by the U.S. Department of Defense and NIH, expected in 2022.
Daxor Corporation (NYSE: DXR), a leader in blood volume measurement technology, announces that CEO Michael Feldschuh will present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021, at 4:30 PM ET. He will discuss Daxor's business model, growth strategy, and next-generation technology. The event will be virtual, allowing investors to register for attendance or request one-on-one meetings. The presentation will be available for live streaming and replay on Daxor's website.
Daxor Corporation (NYSE: DXR) reported a significant 61% increase in Q1 2021 revenue year-over-year, attributed to the easing of COVID restrictions. The company opened five new customer accounts utilizing its BVA-100 Blood Volume Analyzer and anticipates more acquisitions in Q3 2021, expanding its presence in major medical centers. Daxor is enhancing its sales team to support growth, with expectations to access over 70% of client hospitals by the end of Q2 2021. The company is also advancing next-generation diagnostic technologies that aim to improve patient outcomes and operational efficiency.
Daxor Corporation (NYSE: DXR) announces the start of a multi-center clinical trial with Veterans Affairs Medical Centers to assess Blood Volume Analysis (BVA) for managing acute decompensated heart failure (ADHF) using the BVA-100 blood test. The NIH intends to fund this landmark study, which aims to enhance treatment outcomes for over 6 million heart failure patients in the U.S. Previous data indicates that BVA-100 guided care could reduce patient mortality by over 82% and readmissions by 56%. The study is vital for validating Daxor's clinical guidance system and advancing heart failure management.
Daxor Corporation (NYSE: DXR) announced new findings regarding the BVA-100 blood test's effectiveness in managing Postural Tachycardia Syndrome (POTS). Published in the Journal of the American College of Cardiology, the study demonstrated that a high sodium diet increased plasma volume and reduced heart rate in POTS patients. The BVA-100 test provides accurate blood volume measurements, affirming its role as a crucial tool for treatment optimization in POTS. Daxor continues to position itself as a leader in blood volume measurement technology.
Daxor Corporation (NYSE: DXR) announces that President and CEO Michael Feldschuh will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. His presentation on March 24 at 12:30 PM EDT will cover the company's business model, growth strategy, and advancements in blood volume measurement technology, including updates on research and contracts with the US Department of Defense. Investors can register to view the presentation and request one-on-one meetings with Feldschuh.
Daxor Corporation (NYSE: DXR) announced that President and CEO Michael Feldschuh will present at the 2021 Emerging Growth Virtual Conference on March 17-19, 2021. He will discuss Daxor's recent achievements, including revenue growth, research advancements, and new contracts with the US Department of Defense. The company's BVA-100® blood test aims to improve management in critical care, COVID-19, and heart failure. Investors can view the presentation online and request one-on-one meetings with Feldschuh afterward.
Daxor Corporation (NYSE: DXR) has secured a $750,000 phase-two contract from the USAF to enhance its blood volume measurement technology. This contract marks the fourth award from the DoD in two years, totaling over $2 million. The funding will facilitate the development of a new fluorescent tracer and optical sensing technology, expanding the capabilities of the BVA-100 Blood Volume Analyzer for both military and civilian applications. The innovative system aims to improve patient resuscitation and treatment outcomes.
Summary not available.
Daxor Corporation (NYSE: DXR) reported a 50.4% revenue increase for its operating division in fiscal 2020, driven by strong sales and leasing of its blood volume analysis systems and military contracts from the US Department of Defense. The company’s NAV rose to $3.89, a 14% increase from $3.41 in 2019. Additionally, Daxor is advancing next-generation BVA technology with support from the NIH and ongoing clinical studies. The commercialization efforts led by new VP Jean Oertel aim to further expand market reach and enhance revenue growth in the coming year.